Enzyvant signs 25,972 SF lease at Southport Innovation Center

April 27, 2022

Trinity Capital Advisors signed a lease with Enzyvant for 25,972 square feet at Southport Innovation Center, its 95-acre life science and technology campus in Morrisville, NC. The biotech company is slated to occupy 50% of 101 Southcenter Court. The new tenant brings Southport Innovation Center to 87% leased.

“Enzyvant is a terrific addition to the robust biotech ecosystem at Southport Innovation Center,” said Jeff Sheehan, Managing Partner at Trinity Capital Advisors. “We are thrilled to be able to offer them highly customizable lab and manufacturing space in the heart of the Triangle area.”

Enzyvant is an accelerator for transformative regenerative medicines with a focus on tissuebased
therapies for rare conditions. The company, with headquarters in Cambridge, MA, will be expanding its North Carolina operations. The new space will be customized labs and offices, including clean rooms for the manufacturing of their recently approved tissue-based regenerative therapy.

“This new manufacturing facility builds on our Research Triangle Park presence and enables Enzyvant to deliver on our commitment to patients.,” said Larry Weiner, VP of Pharmaceutical Development & Manufacturing at Enzyvant.

John Daly and Josh Stanley of CBRE Raleigh office represented the tenant. Doug Cook, Senior Director at Cushman & Wakefield, and Leasing Representative, Suzanna Nichols represented the landlord.

Trinity Capital, along with additional investors, currently has more than 500,000 square feet of life science space in development and 2.3 million square feet of space in total in the Raleigh-Durham area. The company recently announced plans for Spark Life Science, a 109-acre advanced life science campus in Morrisville that will feature approximately 1.5 million square feet of cutting-edge lab and bio-manufacturing space. In addition to Southport Innovation Center, Trinity Capital owns a 661,000 square foot life science/flex portfolio at Park Point also in the Research Triangle as well as the newly completed Roxboro at Venable Center, an eight-story 202,000 square foot lab and office building in downtown Durham.

About Southport Innovation Center:
Southport Innovation Center is a 95-acre life science and technology campus featuring 17 buildings totaling 911,700 square feet located near the airport in the heart of the Triangle area. The properties are a mix of lab, office, and flex buildings. Since purchasing the property in November 2020, Trinity Capital has completed a number of improvements adding to the vibrancy of the campus. These include a newly remodeled Village Deli and a 7,000 square foot amenity space, the Union, with a state of the art fitness center and locker rooms, lounge, bar and café, conference center, and outdoor gathering space.

Enzyvant is a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases. The company’s first commercial product is U.S. Food and Drug Administration (FDA)-approved RETHYMIC (allogeneic processed thymus tissue-agdc), a tissuebased regenerative therapy for an ultra-rare and life-threatening pediatric immunodeficiency. Enzyvant has distinctive capabilities in expedited development of regenerative therapies for rare diseases. The company has obtained and leveraged multiple regulatory designations including Regenerative Medicine Advanced Therapy, Breakthrough, Fast Track, Rare Pediatric Disease, Orphan Drug, and Advanced Therapies Medicinal Product. Enzyvant is wholly owned by Sumitovant Biopharma Ltd. (wholly owned by Sumitomo Pharma). For more information
about Enzyvant, visit Enzyvant.com.